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A randomized controlled trial on pharmacological
preconditioning in liver surgery using a volatile anesthetic
Abstract
OBJECTIVE: To evaluate the effects of pharmacological preconditioning with a volatile anesthetic in
patients undergoing liver resection with inflow occlusion. BACKGROUND: In liver surgery, ischemic
preconditioning and intermittent clamping are the only established protective strategies to reduce tissue
damage due to ischemia during inflow occlusion. Preconditioning with volatile anesthetics has provided
protection against cardiac and renal ischemic injury in several animal models through NO and HO-1
pathways. But pharmacological preconditioning has never been tested in patients undergoing liver
surgery in a randomized trial. METHODS: Sixty-four patients undergoing liver surgery with inflow
occlusion were randomized intraoperatively for preconditioning with sevoflurane or not
(ClinicalTrials.gov NCT00516711). Anesthesia was performed intravenously with propofol. Thirty
minutes before inflow occlusion propofol was replaced by sevoflurane in the preconditioning group.
Primary endpoint was postoperative liver injury assessed by peak values of liver transaminases.
Postoperative complications were recorded according to an established scoring system. RESULTS:
Sevoflurane preconditioning significantly limited the postoperative increase of serum transaminase
levels by 261 U/L (95% CI, 65 to 458; P = 0.01) for the ALT and by 239 (95% CI, -2 to 480; P = 0.05)
for the AST corresponding to decreases of baseline levels of 35% and 31%, respectively. Patients with
steatosis had an even better benefit than patients without steatosis. The rates of any complication (risk
ratio 0.46; 95% CI, 0.25 to 0.85; P = 0.006) and of severe complications requiring invasive procedures
(risk ratio 0.25; 95% CI, 0.06 to 1.08; P = 0.05) were also lowered by preconditioning. CONCLUSION:
This first randomized trial of pharmacological preconditioning in liver surgery in humans showed a
protective effect of preconditioning with volatile anesthetics. This strategy may provide a new and
easily applicable therapeutic option to protect the liver and to lower complication rates.
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MINIABSTRACT 
Pharmacological preconditioning with volatile anesthetic in liver surgery is protective 
regarding the postoperative increase of transaminases as well as the clinical outcome. The 
protective effect is pronounced in patients with liver steatosis. The study indicates that NO 
may play a role in the protective pathway of volatile anesthetics.
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ABSTRACT 
Objective: To evaluate the effects of pharmacological preconditioning with a volatile 
anesthetic in patients undergoing liver resection with inflow occlusion. 
Background: In liver surgery, ischemic preconditioning and intermittent clamping are the 
only established protective strategies to reduce tissue damage due to ischemia during inflow 
occlusion. Preconditioning with volatile anesthetics has provided protection against cardiac 
and renal ischemic injury in several animal models through NO and HO-1 pathways. But 
pharmacological preconditioning has never been tested in patients undergoing liver surgery in 
a randomized trial. 
Methods: 64 patients undergoing liver surgery with inflow occlusion were randomized 
intraoperatively for preconditioning with sevoflurane or not (ClinicalTrials.gov 
NCT00516711). Anesthesia was performed intravenously with propofol. 30 minutes before 
inflow occlusion propofol was replaced by sevoflurane in the preconditioning group. Primary 
endpoint was postoperative liver injury assessed by peak values of liver transaminases. 
Postoperative complications were recorded according to an established scoring system. 
Results: Sevoflurane preconditioning significantly limited the postoperative increase of 
serum transaminase levels by 261 U/L (95% CI 65 - 458, p=0.01) for the ALT and by 239 
(95% CI -2 - 480, p=0.05) for the AST corresponding to decreases of baseline levels of 35% 
and 31%, respectively. Patients with steatosis had an even better benefit than patients without 
steatosis. The rates of any complication (risk ratio 0.46, 95% CI 0.25 - 0.85, p=0.006) and of 
severe complications requiring invasive procedures (risk ratio 0.25, 95% CI 0.06 - 1.08, 
p=0.05) were also lowered by preconditioning. 
Conclusion: This first randomized trial of pharmacological preconditioning in liver surgery 
in humans showed a protective effect of preconditioning with volatile anesthetics. This 
strategy may provide a new and easily applicable therapeutic option to protect the liver and to 
lower complication rates. 
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Hemorrhage remains a significant concern during major liver resection influencing 
postoperative recovery and long-term survival.1, 2 Inflow occlusion by clamping of the portal 
triad (Pringle maneuver), as routinely used in many centers 3 prevents blood loss during liver 
transsection,4-6 particularly when associated with low central venous pressure (CVP).7 
However Pringle maneuver induces ischemic injury in the remnant liver, which is associated 
with increased morbidity and mortality.8 Diseased livers such as steatotic or fibrotic livers 
may be the most vulnerable to temporary interruption of blood flow. 9-11 
Surgical techniques are known to protect liver cells against subsequent sustained 
ischemia in cases of ischemic-reperfusion injury in animal models 12 as well as in humans.11, 
13 Currently, ischemic preconditioning with continuous clamping, but also intermittent portal 
triad clamping (cycles of 15 minutes of ischemia followed by 5 minutes of reperfusion) are 
the only clinically established protective strategies against liver injury due to prolonged 
ischemia.14, 15 The underlying protective principle of ischemic preconditioning and 
intermittent clamping is a limitation of stress exposure of the liver that triggers natural 
defense mechanisms against subsequent ischemic insults.16 
Pharmacological preconditioning as a hepatoprotective strategy in humans has not yet 
been described, while volatile anesthetic agents such as isoflurane or sevoflurane have been 
widely studied to attenuate cardiac mechanical dysfunction and limit ultrastructural 
abnormality on reperfusion after ischemia in the myocyte.17, 18 Intravenous anesthetics such as 
propofol do not seem to have comparable protective properties.19 It has been shown in a rat 
model that the application of isoflurane before induction of hepatic ischemia protected the 
liver from ischemia-reperfusion injury.20 
Therefore we designed a randomized controlled trial to evaluate the protective effects 
of sevoflurane preconditioning in patients undergoing hepatectomy under inflow occlusion. In 
the presence of sevoflurane, an attenuation of liver injury is hypothesized on the basis of a 
diminished increase of liver transaminases. Our secondary endpoint was to evaluate the 
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impact of sevoflurane preconditioning in reducing postoperative complications. Finally, we 
evaluated inducible nitric oxide synthase (iNOS) expression in liver tissue as a putative 
protective pathway related to the use of sevoflurane. 
 
MATERIAL AND METHODS 
Experimental Design 
Consecutive patients undergoing elective liver resection with inflow occlusion 
between April 2006 and November 2007 were assessed for study eligibility. Exclusion criteria 
for the present study were age < 18 years, liver cirrhosis, additional ablation therapies 
(cryosurgery or radiofrequency), living donors, as well as liver resections without inflow 
occlusion. Enrolled patients were randomized at the beginning of the operation into an 
intervention group (preconditioning with sevoflurane/ sevoflurane group) or a control group 
(propofol group). The randomization sequence without any stratification was generated by 
computer and sealed, consecutively numbered envelopes provided concealment of random 
allocation. Each patient was operated under the supervision of one of two blinded, 
experienced hepatobiliary surgeons. The time of continuous inflow occlusion was adapted as 
needed, but had to exceed 30 minutes. 
The study was approved by the institutional review board for human studies and 
internationally registered at ClinicalTrials.gov NCT00516711. The manuscript complies with 
the CONSORT checklist. Written informed patient consent was obtained from all 
participants. 
 
Anesthesia 
All patients received oral midazolam (7.5 mg) as a premedication. Electrocardiogram, 
radial arterial pressure, arterial oxygen saturation (SaO2) and depth of anesthesia (measured 
by bispectral index) were monitored routinely. If necessary, thoracic epidural anesthesia was 
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performed using continuous application of 0.33% ropivacaine (4 - 8 ml/hour with a bolus 
application of 4 ml after induction of anesthesia). 
General anesthesia was induced with 3 µg/kg fentanyl, target-controlled infusion of 
propofol, set at a plasma target concentration of 4 - 6 µg/ml, and 0.5 mg/kg atracurium. 
Anesthesia was maintained with target-controlled infusion of propofol (plasma target 
concentration of 2 - 4 µg/ml), fentanyl 1 - 2 µg/kg, and atracurium 5 - 10 mg boluses 
according to clinical needs, as well as remifentanil 0.3 - 0.6 µg/kg/min.  
In patients with preconditioning propofol anesthesia was replaced by sevoflurane (Fig. 
1): 30 minutes before induction of ischemia, propofol anesthesia was stopped and replaced by 
sevoflurane (induction of 5 minutes). Pharmacological preconditioning with endexpiratory 
sevoflurane of 3.2 Vol % was performed for 10 minutes. The following 5 minutes were 
utilized to stop sevoflurane application and to replace it by propofol (washout of 5 minutes). 
After a further 10 minutes, ischemia was started for at least 30 minutes. 
 
Surgical Procedure 
Surgical procedures were performed in a standardized manner under the supervision 
of two experienced HPB surgeons. A first liver specimen was taken after laparotomy 
(baseline biopsy). During mobilization of the liver, the time point of 30 minutes before 
clamping of the portal triad was defined by the surgeon and communicated to the 
anesthesiologist. According to the randomization, a pharmacological preconditioning with 
sevoflurane was performed or not, whereby the surgeon was kept blinded for the whole 
operation. Selective devascularisation of the resected specimen was carried out in anatomical 
resections,11 but not in atypical hepatectomies. During resections a low CVP (0 – 5 mm Hg) 
was required. Liver transsection was performed by parenchyma crushing using a small Kelly 
clamp (3 mm diameter tip).6 Small vessels (< 2mm) were coagulated with the irrigated 
bipolar forceps set at 120 W, while all other structures including major intrahepatic bile ducts 
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were ligated or clipped. A stapler device was only used for the transsection of the hepatic 
veins. The time of continuous inflow occlusion was adapted as needed, but had to exceed 30 
minutes, as this is the minimal ischemic period with detectable postoperative liver injury.5 
Inflow occlusion was achieved by the tourniquet technique around the portal triad with a 4-
mm mersilene tape. Separate clamping of aberrant left hepatic arteries was carefully 
performed when present. 30 minutes after reperfusion a second biopsy was performed. 
 
Endpoints 
Each patient was followed for the entire hospitalization. The primary endpoint was 
postoperative hepatocyte injury defined by peak alanine-aminotransferase (ALT) and 
aspartate-aminotransferase (AST) levels over 7 postoperative days. The secondary endpoint 
was postoperative complications as assessed by our treatment-oriented complication score.21 
Grades I, II and IIIa were assessed as minor, while grades IIIb, IV and V were major 
complications, requiring interventions with general anesthesia and/or intensive care 
management. Additional endpoints were peak values of white blood cells (WBC), bilirubin, 
alkaline phosphatase (ALP) and creatinine levels as well as length of hospital stay, length of 
intensive care unit (ICU) stay, and operating time. Additionally, histological evaluation of 
steatosis and fibrosis, as well as the quantification of iNOS gene expression were determined. 
 
Histological Evaluation 
Liver resection specimens or intraoperative liver biopsies (baseline biopsy) were 
evaluated by a single pathologist (WJ) for the presence of steatosis and fibrosis. Using 
haematoxylin and eosin (H&E) stained sections, the degree of total steatosis was graded as 
absent (< 10%), mild (10 - 30%), moderate (> 30 - 60%), or severe (> 60%) based on the 
percentage of hepatocytes with fat droplets. Liver fibrosis was quantified according to the 
METAVIR score using sirius red stained sections: absent (F0), portal fibrosis without septa 
 7
(F1), portal fibrosis with rare septa (F2), numerous septa (F3) and cirrhosis (F4).22 
Histological analysis was performed without knowledge of the postoperative outcome of 
patients. 
 
Determination of Inducible Nitric Oxide Synthase (iNOS) 
Total RNA was extracted from both biopsies and reverse transcribed using a special 
kit (Taqman® Reverse Transcription Reagents). Quantitative PCR (QPCR) was carried out 
with a 7500 Fast Real Time PCR System. The following primers were used for the QPCR: 
human iNOS (Hs00167257-m1), and human 18S (Hs99999901-s1). QPCR was performed 
using Taqman® Universal PCR Mastermix (Nr. 4304437) according to the manufacturer’s 
protocol. Gene expression was normalized to 18S, and increase in iNOS gene expression was 
calculated with the comparative CT method of gene expression before and after ischemia, 
respectively. iNOS gene expression from baseline biopsy was assigned as value of 1. All 
products were purchased from Applied Biosystems, Foster City, CA, USA. 
 
Statistical Analysis 
In an intention-to-treat analysis we first compared primary and secondary continuous 
endpoints between groups using two-sample t-tests. In addition, we adjusted these analyses 
for baseline transaminases and bilirubin levels, for preoperative chemotherapy (yes/no) and 
pringle time in multivariable linear regression analyses. We calculated risk ratios for binary 
outcomes (complications) and tested for statistical significance using Fisher’s exact test.  
We conducted a limited number of subgroup analyses with three prespecified 
predictors that may modify the effects of pharmacological preconditioning on postoperative 
hepatocyte injury (ALT/AST). We assessed the effect of steatosis (yes/no, defined by the 
presence of at least 10% of hepatocytes containing fat droplets), preoperative chemotherapy 
(yes/no) and age (< 60years/ ≥ 60 years) by introducing interaction terms into the regression 
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analyses, which is the most rigorous and widely recommended approach for subgroup 
analyses.23 Because of the low power of interaction testing to detect subgroup effects we 
considered subgroup effects to be significant if p ≤ 0.10.24 All analyses were conducted using 
STATA (STATA for Windows, version 9.2, Stata Corp; College Station, TX). 
 
RESULTS 
What was the Patient Selection for Study Participation? 
Figure 2 shows the study flow from screening of potential participants to the final 
assessment. The main reason for non-inclusion of a number of patients, was the concomitant 
availability of a second randomized controlled trial focusing on liver regeneration after major 
liver resection. Furthermore, after randomization, 6 patients had to be excluded because of 
violation of the study protocol due to the intraoperative decision of an approach without 
Pringle maneuver (2 patients in the control group) or because of a delay of more than 30 
minutes between preconditioning and hepatic inflow occlusion (4 patients in the 
preconditioning group). 
 
Was the Preconditioning Group Comparable with the Control Group? 
30 patients were included in the preconditioning group (sevoflurane group) and 34 
patients in the control group (propofol group). Table 1 shows the patients characteristics and 
baseline values of the outcome parameters. The mean age was slightly different, 54.2 years in 
the sevoflurane group versus 57.8 years in the control group, with 16 and 19 males, 
respectively. American Society of Anesthesiologists (ASA) physical status classification, type 
of disease, histology of liver parenchyma, and the use of chemotherapy prior resection were 
distributed similarly between both groups. None of the parameters were statistically different. 
Thirty-three patients were operated for liver metastasis from colorectal cancer, 6 for 
echinococcosis, 3 for hepatocellular carcinoma, 3 for cholangiocarcinoma, 1 for a 
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neuroendocrine tumor, 11 for other benign lesions such as liver adenoma, focal nodular 
hyperplasia, hemangioma or cysts, and 7 for other malign tumors (various kinds of metastatic 
diseases) (Tab. 1). Twenty-six patients underwent a major hepatectomy, of whom 8 had an 
anatomic right hemi-hepatectomy (SV – VIII), 5 had a left hemi-hepatectomy (SI – IV), 7 had 
extended right hemi-hepatectomy (SIV – VIII), and 6 had an atypical major resection (Tab. 
2). Intraoperative parameters as shown in Table 2 were similar in both groups. The mean time 
of inflow occlusion was 36 minutes (sevoflurane group) and 35 minutes (control group) 
respectively, while the operating time was around 4 hours.  
 
Did Pharmacological Preconditioning Prevent Postoperative Liver Injury? 
The degree of ischemia and reperfusion injury of the liver was assessed by 
postoperative peak serum ALT and AST levels. The peak of the transaminases occurred 
between 6 hours after the end of surgery and the third postoperative day. In most of the 
patients, ALT and AST levels returned to normal within 7 days. Sevoflurane preconditioning 
significantly lowered peak ALT levels by 261 U/L (95% CI 65 - 458, p=0.01) and AST levels 
by 239 U/L (95% CI -2 - 480, p=0.05) corresponding to decreases of baseline levels of 35% 
and 31%, respectively (Tab. 3). Unadjusted and adjusted results were almost identical. Other 
liver parameters such as bilirubin and ALP, but also peak values of WBC and creatinine did 
not reach statistical differences. 
 
Did Pharmacological Preconditioning Influence the Clinical Outcome after Liver 
Surgery?  
One patient in each group (both underwent extended right hemihepatectomy for hilar 
cholangiocarcinoma) died within 1 week following major hepatectomy. Death occurred due 
to sepsis. The complication rate was significantly lower in the sevoflurane group compared 
with the in the propofol group  (30% vs 65%, risk ratio 0.46, 95% CI 0.25 - 0.85, p=0.006) 
 10
(Tab. 4). There was no significant differences regarding minor complications among grade I, 
II and IIIa. However, major complications (grade IIIb, IV, and V) differed significantly 
between groups with 6.7% vs 26.5% (p=0.05). The mean hospital stay was 2 days shorter in 
the sevoflurane group (11 vs 13 days), but without statistical significance. ICU stay was 
comparable between groups. 
 
Is Inducible Nitric Oxide Synthase (iNOS) Involved in Cellular Signaling in 
Pharmacological Preconditioning in Liver? 
Nitric Oxide (NO) has been proposed to mediate the beneficial effects of ischemic 
preconditioning in the liver.25, 26 But it also seems to play an essential role in pharmacological 
preconditioning with isoflurane in myocytes.27 Therefore the expression of iNOS mRNA was 
compared between pre- and postresection liver biopsies. iNOS mRNA was significantly 
upregulated in the preconditioning group (5.96 ± 7.12) compared with the control group (1.3 
± 1.15, p=0.001) in (Tab. 3). 
 
Does Liver Steatosis, Preoperative Chemotherapy or Age of Patients Influence the 
Protective Effect of Pharmacological Preconditioning? 
 30 out of 64 patients (47%) had steatosis with > 10% of hepatocytes containing fat 
droplets (9 of these patients had more than 30%). As shown in Fig. 3a & b pharmacological 
preconditioning demonstrated strong protective effects in steatotic patients in terms of 
postoperative serum peak ALT und AST levels compared with non-steatotic patients. 
Subgroup effects were significant for both peak ALT (p=0.03) und AST levels (p=0.08). 
Although preoperative chemotherapy favored preconditioning with differences in peak 
transaminases between control and preconditioning group in patients with chemotherapy of 
361 U/L (ALT) and 430 U/L (AST) compared to 174 U/L and 16 U/L without chemotherapy, 
results were not significantly different (Fig. 3a & b). Also no significant difference was found 
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for the effect regarding age. The difference in peak ALT between control and preconditioning 
group was 481 U/L (554 U/L for AST) in patients ≥ 60 years and 207 U/L (94 U/L for AST) 
in patients < 60 years (Fig. 3a & b).
 
DISCUSSION 
This randomized controlled trial demonstrates for the first time the protective effects 
of pharmacological preconditioning in patients undergoing liver resection with inflow 
occlusion. Not only was postoperative liver injury attenuated, as measured by serial serum 
levels of transaminases, but also clinical outcome was significantly improved by 
pharmacological preconditioning. The observed protective effects were more pronounced in 
patients with liver steatosis. This study additionally suggests that NO may mediate the 
protective pathway of volatile anesthetics. 
Numerous strategies have been designed to reduce ischemia-reperfusion injury after 
liver resection. Basically, inflow occlusion is less harmful than total vascular exclusion.28 
Two protective strategies to prevent ischemic-reperfusion injury have been clinically 
accepted: ischemic preconditioning5, 11, 29 and intermittent clamping14, 30 of the portal triad. 
Ischemic preconditioning consists of a short period of inflow occlusion, usually 5-10 minutes, 
followed by 5 minutes of reperfusion prior to the actual inflow occlusion for the operation. 
Intermittent clamping consists of 10 minute intervals of reperfusion during the whole period 
of the operation, and although apparently more protective, may lead to significant blood 
loss.14 Both procedures require a surgical intervention and prolong the overall time of the 
surgical procedure. Hence, a pharmacological approach not requiring additional surgical 
procedures is a more attractive alternative than the established surgical strategies. 
Pharmacological preconditioning with a volatile anesthetic is a new approach in liver 
surgery. Beneficial results in clinical trials, particularly of preconditioning with sevoflurane, 
have been shown in cardiac surgery,31, 32 while in liver surgery only one animal study is 
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available.20 This study established for the first time that volatile anesthetics confer protection 
to livers exposed to ischemia and reperfusion in patients requiring major liver surgery. 
The study design, particularly regarding the endpoints, was based on our previous 
clinical5, 11, 14 and experimental33-35 experience with such studies. Patients with cirrhosis were 
excluded from the study because there might have been different and more severe effects of 
inflow occlusion. Additionally, some patients were not included because they were already 
participating in another ongoing randomized controlled trial (RCT), focused on regeneration 
after major liver resection. At our center, more than 95% of the patients with liver resections 
are included in prospective studies. This high inclusion rate is not normally attainable by one 
single RCT, due to predefined inclusion and exclusion criteria. At our center, we aim to have 
at least two parallel ongoing trials to make participation in a RCT possible for almost all of 
our patients. On the other hand, some interferences concerning inclusion of patients between 
patients can occur. As shown in Fig 2, patient collection was consecutive and unselective 
aside of the parallel RCT. 
Considering the entire series, we found statistically significant protection from 
preconditioning with sevoflurane in terms of postoperative peak ALT and AST levels. These 
results highlight the overall protective effects against reperfusion injury considering the 
heterogeneous groups of patients with ischemic times of 30 – 50 minutes, the often use of 
additional procedures, and patients with or without hepatic steatosis. The results were 
adjusted according to potential confounders (Table 3) to exclude any influence of minimal 
differences between the patient groups, which occur despite the randomization of patients. 
The decrease of peak transaminases due to pharmacological preconditioning of around 30% 
appears comparable to the effect of ischemic preconditioning.11 
Postoperative morbidity and mortality were evaluated using a standardized 
classification system enabling stratification of complications by severity.21 The overall 
morbidity rate of 45%, the mortality rate of 3% and the incidence of severe complications 
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(grades IIIb – V) of 17% were comparable to previously published data after liver resection.11, 
14, 36, 37 The present study demonstrated significantly improved clinical outcome after 
pharmacological preconditioning: on the one hand regarding overall complication rates (65% 
vs. 30%, p=0.006) and on the other regarding major complication (Grade IIIb to V) (27% vs 
7%, p=0.05). This finding underscores the potentially powerful protective effects of volatile 
anesthetics, as none of the previous trials on surgical preconditioning or intermittent clamping 
could show significant differences regarding clinical outcome. A possible explanation for this 
phenomenon might be the release of inflammatory mediators upon hepatic ischemia-
reperfusion, which could also trigger a proinflammatory cascade in organs other than the 
liver. Several studies have stressed the importance of toll-like receptor4 (TLR4) in the 
pathophysiology of ischemia-reperfusion in the heart,38 kidney,39 and liver.40 Theoretically, 
mediators released upon reperfusion might also induce TLR4 expression in other organs, 
where the systemic application of the volatile anesthetic could interfere, either by decreasing 
enhanced TLR4 expression or by blocking these receptors. Further studies have to be 
performed to gain more insight into these signaling pathways. 
The mechanisms of protection of hepatocytes due to pharmacological preconditioning 
remain unclear and may involve several pathways. Barrier et al. demonstrated the modulation 
of gene expression due to ischemic preconditioning 26. Particularly the upregulation of iNOS 
confirms the hypothesis that preconditioning has been linked to NO production. In our study, 
the expression of iNOS upon reperfusion significantly increased compared to the baseline 
value in the preconditioning group, although the second liver biopsy was performed after only 
30 minutes of reperfusion. This indicates a potential protective role of NO in pharmacological 
preconditioning. NO is also a key signaling component involved in preconditioning elicited 
by volatile anesthetics in the myocyte, activating protein kinase C,27 which ultimately 
activates sarcolemmal and mitochondrial KATP channels. 
 14
There is growing evidence that liver steatosis is associated with impaired outcome 
after hepatic resection.41, 42 43 Subgroup analysis of previous studies has demonstrated a 
higher protective effect of ischemic preconditioning5 as well as of intermittent clamping14, 30 
in steatotic livers, an effect possibly associated with the preservation of ATP during 
ischemia.11 Our data confirm higher degree of protection in steatotic livers, also by 
pharmacological preconditioning (Figures 3a & b). Although this study was small for 
subgroup analyses and despite the fact that interaction testing has low power to detect 
subgroup effects we found strong effect modification by steatosis (p for subgroup analysis = 
0.03 for ALT and 0.08 for AST). We considered the subgroup effects to be significant if p 
values for the interaction term was >0.10 because of the low power of this test as did others.24 
Previous studies have demonstrated this effect in liver steatosis of > 25% and > 30%, 
respectively.11, 14 
An increasing number of patients with tumors undergo extensive chemotherapy with 
multiple drugs prior to surgery, impairing the postoperative outcome.8 Drugs such as 
irinotecan (Campto, Pfizer®) and, to a lesser degree, oxaliplatin (Eloxatin, Sanofi, Aventis®) 
have been associated with the development of steatohepatitis,44, 45 while bevacizumab 
(Avastin, Hoffmann-LaRoche®), a monoclonal antibody, impairs liver regeneration and 
wound healing through its regulation of angiogenesis.46, 47 The present study did not show a 
significant improvement of the protective effect in chemotherapeutic livers (Figures 3a & b). 
The sample size to negate this effect definitively might have been too small, and needs to be 
addressed in larger studies. 
In contrast to previous observations in ischemic preconditioning, age had no 
significant influence on the protective effect of pharmacological preconditioning (Fig 3a & b). 
However the beneficial effect was higher in patients above 60 years. We previously identified 
age as a factor influencing the effect of ischemic preconditioning in a multivariate analysis, 
and suggested that tolerance of hepatocytes against ischemic injury might be different in 
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younger compared to older patients.11 The age limit for ischemic preconditioning was 
approximately 60 years, and only patients with age below benefited from this strategy.  
Although the results of the primary endpoint showed a number of significant effects, 
the sample size is relatively small. Therefore interpretation of subgroup analysis, in particular, 
needs to be done carefully. This trial is focused on blood parameters and clinical outcome, 
while a pathway of the protective effect can be hypothesized. Investigations concerning the 
mechanism in animal models are requested. Further trials on the protective effect of different 
applications of sevoflurane would be of major interest. 
In conclusion, this trial provides evidence of the protective effect of preconditioning 
with volatile anesthetics on ischemic/ reperfusion injury in patients with liver resection. 
Pharmacological preconditioning prevents hepatic injury defined by low levels of 
transaminases but also improves the clinical outcome, particularly in patients with an 
increased risk of postoperative liver failure such as those with steatosis. This strategy, 
although needing further investigations, may provide a new and easily applicable therapeutic 
option to protect the liver. 
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FIGURES 
Fig. 1  
Treatment Protocol of Preconditioning and Control Group. 
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Fig. 2 
Flow of Participants through Study. 
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Fig. 3a 
Subgroup Effects on ALT. 
 
 
 
 
Fig. 3b 
Subgroup Effects on AST. 
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TABLES 
 
TABLE 1: BASELINE CHARACTERISTICS 
 
 PRECONDITIONING CONTROL 
Number  30 34 
Age (years): mean (SD) 
54.23 
(12.74) 
57.82  
(12.82) 
Gender male/female (%) 
 
16/14 
(53.3/46.7) 
19/15 
 (57.6/42.4) 
Primary disease (number) 
Echinococcosis  
Colorectal metastasis 
Neuroendocrine tumor 
Hepatocellular carcinoma 
Cholangiocarcinoma 
Other benign lesions 
Other malign tumor 
 
4 
16 
0 
1 
1 
5 
3 
 
2 
17 
1 
2 
2 
6 
4 
Malign/benign disease, number 21/9 26/8 
Baseline ALT: mean (SD) U/L 
 
32.53 
(20.15) 
39.91  
(43.25) 
Baseline AST: mean (SD) U/L 
 
32.83 
(15.67) 
34.21 
 (20.86) 
Steatosis, number 
None/mild/moderate 
(<10/10-30/>30) 
 
18/9/3 
 
16/12/6 
Fibrosis Ishak score, number 
0/1/2/3 
 
16/8/4/2 
 
20/7/2/5 
ASA: - mean (SD) 
          
         - I/II/III 
2.10 
(0.66) 
5/17/8 
2.11  
(0.54) 
3/24/7 
Charlson Index: mean (SD) 
5.17 
(3.13) 
4.88  
(2.86) 
Bilirubin mean (SD) mmol/L 
12.77 
(10.67) 
11.74  
(11.11) 
Preop. chemotherapy 
yes/no 
 
15/15 
 
19/15 
SD: standard deviation 
Preop.: preoperativ
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TABLE 2: INTRAOPERATIVE PARAMETERS 
 
 PRECONDITIONING CONTROL 
Major/minor resection, number 12/18 14/20 
Additional surgery 
None/colorectal/other 
26/2/2 26/2/4 
Hepatectomy, number 
First/second/third/>third 
23/6/1/0 31/1/1/1 
Pringle time mean (SD) 
36.03 
(5.62) 
35.12 
(6.32) 
Operation time mean (SD) 
259.83 
(87.81) 
267.65 
(95.72) 
 
Major resection: ≥4 segments 
Minor resection: < 4 segments 
SD: standard deviation 
 
TAB. 3: POSTOPERATIVE VALUES 
 PRECONDITIONING CONTROL ADJUSTED 
DIFFERENCE 
Peak ALT mean (SD) 
U/L 
463.53 
(287.95) 
717.71 
(497.47) 
261.48 
(65.43 - 457.54, p =0 .01) 
Peak AST mean (SD) 
U/L 
507.53 
(291.76) 
733.35 
(636.51) 
239.10 
( -1.84 - 480.04, p =0 .05) 
Peak bilirubin mean (SD) 
mmol/L 
33.67 
(26.89) 
44.47 
(63.93) 
12.91 
( -16.92 - 42.74, p =0 .39) 
Peak ALP mean (SD) 
mmol/L 
154.77 
(104.08) 
162.12 
(109.35) 
2.00 
( -58.83 - 62.84, p =0 .95) 
Peak WBC mean (SD) 
x103/mL 
11.48 
(3.34) 
13.03 
( 3.54) 
1.11 
( -0.59 - 2.80, p =0 .20) 
Peak creatinine mean 
(SD) 
93.67 
(63.99) 
95.62 
(47.71) 
-4.03 
( -37.77 - 29.72, p = 0 .81) 
mRNA for iNOS 5.96 (7.12) 
1.3 
(1.15) 
-4.41 
( -7.50 - -1.33, p=0.001) 
 
Adjusted for age, baseline bilirubin, steatosis, preoperative chemotherapy, pringle time, baseline 
ALT/AST  
 TAB. 4: POSTOPERATIVE COMPLICATION, ICU STAY, AND HOSPITAL STAY  
 
 PRECONDITIONING CONTROL Risk ratio 
Complications    
Any, n (%) 9 (30.0) 
22  
(64.7) 
0.46 
 (0.25-0.85, p=0.006) 
Major (IIIb-V) 2  (6.7) 
9  
(26.5) 
0.25  
(0.06-1.08, p=0.05) 
ICU stay, number 
(%) 
4 
 (13.3) 
9  
(26.5) 
0.50  
(0.17-1.47, p=0.23) 
    
 
   Adjusted difference 
Hospital stay 
(days):  
mean (SD) 
10.93 
 (4.40) 
12.79 
 (8.86) 
2.00 
 (-1.70 - 5.70, p=0.28) 
 
 
Adjusted for age, baseline bilirubin, steatosis, preoperative chemotherapy, 
pringle time, baseline ALT/AST  
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